|
|
| Packaging Goes Green
| | | By
Hallie Forcinio
| | | Pharmaceutical companies get ideas for sustainable packaging from other industries.
| | | How to Develop a Practical (and Compliant) Vendor Qualification Program
| | | By
Nancy Cafmeyer
,
Jonathan M. Lewis
| | | This article introduces the "Q.U.E.S.T." approach for vendor qualification, a practical and compliant methodology for pharmaceutical and biopharmaceutical companies to qualify vendors and hence make well-informed purchasing-related decisions.
| | | CROs and CMOs Go Further East
| | | By
Angie Drakulich
| | | Contract research organizations such as Covance are heading further east through Europe.
| | | Multinational Firms Stake Claims
| | | By
Angie Drakulich
| | | This article is part of a Special Report on the Emerging Markets of The East, October 2009
| | | Standard-Setting Bodies Engage Russia
| | | By
Angie Drakulich
| | | As the pharmaceutical industry moves further into Central and Eastern Europe and the Commonwealth of Independent States, several standard-setting and regulatory bodies are also increasing collaboration in the region, particularly in Russia.
| |
|
|
|
|
|
|
|
|
|
| Critical Challenges to Implementing QbD: A Q&A with FDA
| | | By
Angie Drakulich
| | | Officials from the US Food and Drug Administration discuss best practices for applying quality-by-design concepts. This article contains bonus online-exclusive material.
| | | Global Regulatory Submissions for QbD: Wyeth's Experience in the CMC Pilot
| | | By
Thirunellai G. Venkateshwaran
,
Stephen P. Simmons
,
Nirdosh Jagota
,
Donald G. Esherick
,
Patricia Foti Mann
| | | Representatives of one pilot program participant, Wyeth, outline the experiences and lessons learned for implementing a science- and risk-based approach to drug-development and manufacturing.
| | | Equivalence by Design for Advanced Dosage Forms and Drug Products
| | | By
Mei-Ling Chen
| | | FDA has been encouraging drug sponsors to use a systematic approach such as quality-by-design principles for pharmaceutical development.
| | | The Relevance of Continuous Solid Oral Dosage Processing and NIR Spectroscopy In Meeting the Needs of QbD and PAT
| | | By
Thomas S. Chirkot
| | | The author discusses control strategies via near infrared instrumentation for continuous mixing, granulation, drying, and extrusion with a more focused detail on mixing.
| | | Quality by Design for Generic Drugs
| | | By
Lawrence X. Yu
,
Robert Lionberger
,
Michael C. Olson
,
Gordon Johnston
,
Gary Buehler
,
Helen Winkle
| | | The authors relay the outcome of a two-day workshop that brought together regulators and generic-drug industry representatives.
| | | Question-Based Review: An FDA Reviewer's Perspective
| | | By
David J. Skanchy
| | | The author analyzes, from an agency perspective, whether question-based review has improved product quality or made the review process easier for regulators or for industry.
| | | Building a Framework for Quality by Design
| | | By
Ronald D. Snee
| | | The author describes the framework needed to implement QbD and achieve the deeper process understanding that is fundamental to QbD.
| | | Academia Tackles QbD Science: NIPTE Carries out FDA Grant and Educational Initiatives
| | | By
Angie Drakulich
| | | A review of NIPTE's core projects and its plans for training-and retraining-the pharmaceutical industry.
| |
|
|
|
|
|
|
| Sizing Up the CDMO Market
| | | By
Jim Miller
| | | A new analysis highlights growth drivers and challenges for clinical supply-chain services.
| |
|
|
|
|
|
|
| Sneaky and Suspicious
| | | By
Control, a senior compliance officer
| | | Like life, the workplace also can have many surprises.
| |
|
|
|
|
|
|
|
|
|
|
|
|
| Inside USP: Characterization of Heparin Products
| | | By
Anita Y. Szajek
,
Tina S. Morris
| | | USP workshop participants support new methods to safeguard heparin products but desire international harmonization. This article contains bonus online-exclusive material.
| |
|
|
|
|
|
|
| Report From: India
| | | By
A. Nair
| | | Pharmaceutical companies in India have had a hold on the biotechnology sector for many years, and they're not about to let the follow-on biologics market pass them by.
| |
|
|
|
|
|
|
|
|
|
| In the Spotlight
| | | Editors' Picks of Pharmaceutical Science & Technology Innovations
| |
|